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Disclosures: None declared.Cystic ﬁbrosis (CF) is a chronic, life-threatening genetic
disease caused by loss-of-function mutations in the CF
transmembrane conductance regulator gene (CFTR).1,2
Notwithstanding the considerable ethnic and geographic
variability in the frequency of CF, the mean incidence of 1
in 2500 live births makes CF the most frequent severe
autosomal recessive disease in the white population.3 CF is
characterized by wide genetic and clinical heterogeneity,
which complicates diagnosis, prognosis, and therapy. From
birth to adulthood, there is considerable variability in the
severity and rate of disease progression in CF, with varying
clinical presentations and different organs involved at
different ages.4 Often, great phenotypic variability arises
from even a single CFTR genotype.5,6
More than 2000 different CFTR sequence variations,
includingCF-causingmutations and polymorphisms, have been
reported (CFTR1 database, http://www.genet.sickkids.on.ca,stigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orglast accessed May 15, 2017). Also in limited geographic
areas, CFTR shows a complete catalog of mutation types
in exons, introns, the 50-ﬂanking region, and the 30-
untranslated region, that is, point mutations, small insertions
and deletions, complex alleles, and large genomic
rearrangements.5,7e12 This genetic heterogeneity greatly af-
fects the allele detection rate (DR) of genetic tests, which is
deﬁned as the overall frequency of mutant alleles (of all of the
mutant alleles present), as evidenced by a genetic test. For
example, the DRs of the 23-mutation panel established by the
American Congress of Obstetrician and Gynecologist and theolecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
An NGS Mutation Panel for Cystic FibrosisAmerican College of Medical Genetics differ substantially
between various geographic regions, ranging from 49% to
94%.13,14 This genetic heterogeneity is further enhanced if
various well-recognized clinical forms of CF, such as classic
CF, CFTR-related disorders, and congenital bilateral absence
of vas deferens, are taken into consideration.15,16 The same
genetic test may have very different DRs, depending on its
application in these different clinical forms.17 In this article, CF
refers to the classic form of the disease and excludes CFTR-
related disorders and congenital bilateral absence of vas defer-
ens, which will be speciﬁcally mentioned when appropriate.
Limiting the scope to CF, but considering geographic areas
with high genetic heterogeneity, an extended Sanger
sequencing protocol of the 50-ﬂanking region, 27 exons and
proximal intronic ﬂanking regions, plus selected deep
intronic zones for speciﬁc intron mutations in CFTR, have
shown DRs of up to 97%.5,17 An additional search for large
CFTR rearrangements showed a DR increment of approxi-
mately 2%.5,9,17 The high DRs of approaches with extended
genetic characterization seem to be conﬁrmed by next-
generation sequencing (NGS) technology, which has been
recently used for sequence and copy number variation (CNV)
analyses of CFTR.18e27 NGS has been used mainly in vali-
dation studies and has been performed on a limited number of
samples in comparisons of the performance of NGS to those
of classic Sanger sequencing and multiplex ligation-
dependent probe ampliﬁcation (MLPA). Although the NGS
approach provides an obvious reduction in cost per base, and
an actual possibility of multiple-gene analysis for multigenic
disorders, the suitability of this approach in monogenic dis-
orders is still debated. In particular, the classic sequencing
approach and MLPA have shown excellent laboratory oper-
ative characteristics for CFTR.5,17,28,29
Despite the excellent operative characteristics of experi-
mental approaches based on both extended sequencing and
large rearrangement search,which arewelcomed for diagnostic
purposes, these approachesmay not be suitable for other health
programs, such as neonatal and carrier screening. In fact, in
addition to the obvious problems of cost and time, the func-
tional characterization of all of the possibly identiﬁed sequence
variations and the subsequent assignment of their clinical sig-
niﬁcance30 may be impossible tasks. Consequently, several
efforts have been made to develop experimental approaches
based on selected panels of known CF-causing mutations.31,32
In this case, the DR of the selected panel of mutations in
populations of various ethnographic origins and/or with
various CF clinical forms invariably arose as a crucial vari-
able.17 NGS platforms seem to be particularly suited to the
development of mutation panels with high a mutation number
and, consequently, a highDR. However, at themoment, only a
small number of articles have addressed speciﬁc CFTR muta-
tion panels based on NGS approaches.33
In this work, we developed, validated, and tested a high-
throughput, NGS-based approach using a customized mutation
panel containing 188 CF-causing mutations in CFTR. We
analyzed1828 subjects referred for diagnosis and a case series ofThe Journal of Molecular Diagnostics - jmd.amjpathol.org1138 patients with CF (646 patients from northern Italy and 492
patients from central Italy). We called this assay 188-CF-NGS.
This approach revealedDRs of 95.0% and 95.6% inCF patients
from central and northern Italy, respectively.Also in geographic
regions with high genetic heterogeneity (such as Italy), a suit-
ably customized and reasonably large panel ofCFTRmutations,
together with an NGS-based approach, allows the attainment of
a high DR that is deﬁnitely suited for diagnostic purposes, at
least in CF, and for neonatal and carrier screening.
Materials and Methods
Study Design and Case Series
We designed a speciﬁc, customized panel of 188 CF-causing
mutations, described in Supplemental Table S1. The mutations
were included based on their high frequency in the Italian
population and their documented associations with CF. Fre-
quency information was obtained using the data on the fre-
quency of CF mutations in Italian patients in the
literature,5,34e39 from the 2010Report of the ItalianCFRegister
(http://www.registroitalianoﬁbrosicistica.it, last accessed
January 31, 2017), as well as from personal communication
with some Italian CF centers and laboratories. The
characterization of the mutations as CF causing was obtained
from data on the functional effect from the North American
CFTR2 (Clinical and Functional Translation of CFTR, https://
cftr2.org, last accessed January 31, 2017) project40 and from
the literature.5,34,35,41 With this panel of CFTR mutations, we
optimized an NGS-based assay we called 188-CF-NGS.
Our assay underwent six steps of validation (Figure 1). If
allowed by the overall number of mutant alleles, each mu-
tation was validated in at least three independent samples.
Also, possible differences in quality, analytical sensitivity,
and analytical speciﬁcity of the 188-CF-NGS assay between
analysis of dried blood spots (DBSs) and analysis of
genomic DNA were evaluated.
The ﬁrst validation step was the analysis of 48 selected
DBSs (referred to the Newborn Screening Laboratory,
ASST Fatebenefratelli SaccodPO Ospedale dei Bambini
“V. Buzzi,” Milan, Italy) that were previously investigated
by mass spectrometry assay (Mass Spectrometry Assay).
The DBSs were obtained from neonates screened as positive
through the immunoreactive trypsinogen assay. The
composition of this subset of DBS samples was as follows:
eight homozygotes, 26 compound heterozygotes, four het-
erozygotes, and 10 with no CFTR mutation.
The second validation step was the analysis of 24
genomic DNA samples extracted from peripheral blood
(referred to the Medical Genetics Laboratory, Fondazione
Istituto di Ricovero e Cura a Carattere Scientiﬁco Ca’
Granda Ospedale Maggiore Policlinico, Milan, Italy), which
had been genotyped by conﬁrmatory methods
(Conﬁrmatory Methods). The subset of 24 genomic DNA
samples consisted of nine compound heterozygotes, eight
heterozygotes, and seven with no CFTR mutation.789
1st validation step: 
48 DBS
(with already known mutations)
2nd validation step: 
24 genomic DNA
(with already known mutations)
3rd validation step: 
1378 DBS
(mutations found confirmed
next)
4th validation step: 
378 genomic DNA
(mutations found confirmed
next)
5th validation step: 
1138 genomic DNA
with already known mutations
6th validation step: 
(theoretical for remaining
mutations)
Study workflow
Mutations experimentally validated
- in this step: 14
- overall: 14
Mutations experimentally validated
- additional in this step: 9
- overall: 23
Mutations experimentally validated
- additional in this step: 32
- overall: 55
Mutations experimentally validated
- additional in this step: 15
- overall: 70
Mutations experimentally validated
- additional in this step: 84
- overall: 154
Mutations experimentally validated
- additional in this step: 0
- overall: 154
Mutations theoretically validated
- in this step and overall: 34
Figure 1 Study workﬂow of the 188-CF-NGS assay. The validation steps,
specimens used, and number of mutations validated at each step, as well as
overall, are reported. DBS, dried blood spots.
Lucarelli et alIn the third validation step, 1378 DBSs from neonates
(referred to the Newborn Screening Laboratory, Azienda
Socio Sanitaria Territoriale Fatebenefratelli SaccodPO
Ospedale dei Bambini “V. Buzzi,” Milan, Italy) with elevated
levels of immunoreactive trypsinogen at neonatal screening
were analyzed for mutations using our 188-CF-NGS assay.
All of the identiﬁed mutations were subsequently conﬁrmed
by conﬁrmatory methods (Conﬁrmatory Methods).
In the fourth validation step, 378 genomic DNA samples
from subjects referred for genetic analysis (to the Medical
Genetics Laboratory, Fondazione Istituto di Ricovero e Cura
a Carattere Scientiﬁco Ca’ Granda Ospedale Maggiore Poli-
clinico, Milan, Italy) were analyzed using the 188-CF-NGS
assay. A subset of 325 subjects underwent carrier screening790or carrier testing (211 for family history, 98 as partners of
carriers, and 16 for consanguinity), and another subset (53
subjects) were analyzed for hyperechogenic bowels. All of
the identiﬁed mutations were subsequently conﬁrmed by
conﬁrmatory methods (Conﬁrmatory Methods).
To complete the experimental validation of all of the
mutations available in our case series, we applied a ﬁfth
validation step. We used samples from a case series
comprising 1138 patients affected by CF and diagnosed ac-
cording to the present guidelines41: 646 from northern Italy
(referred to the Lombardia Regional Reference CF Center)
and 492 from central Italy (referred to the Lazio Regional
Reference CF Center). Patients with clinical manifestations
associated with CFTR dysfunction but whose conditions did
not fulﬁll the diagnostic criteria for CF (namely,
CFTRerelated disorders or congenital bilateral absence of
vas deferens15) were not included in the case series. In the
cohort from northern Italy, there were 149 patients (23%)
with pancreatic sufﬁciency and 497 patients (77%) with
pancreatic insufﬁciency. The age range was 2 months to 65
years. In the cohort from central Italy, there were 138 pa-
tients (28%) with pancreatic sufﬁciency and 354 patients
(72%) with pancreatic insufﬁciency. The age range was 6
months to 58 years. All of the patients had undergone genetic
studies, and their mutations had been identiﬁed/conﬁrmed by
conﬁrmatory methods (Conﬁrmatory Methods). This case
series was also used for calculating the DRs of the 188-CF-
NGS assay (in Lombardia and Lazio regions).
In the sixth validation step, all of the mutations not
validated in steps 1 to 4 and not present in our case series
underwent theoretical validation, also by a check of the high
coverage of the corresponding targeted regions. We did not
detect false-negatives related to these mutations.
All subjects provided informed consent to use the de-
identiﬁed biological samples for scientiﬁc study.
DNA Extraction
Genomic DNA from peripheral blood samples, collected in
EDTA tubes, was extracted from 400 mL of blood using a
QiaSymphony DSP DNA Mini Kit (Qiagen, Hilden, Ger-
many), according to the manufacturer’s automated protocol.
For the DBS samples, DNA was extracted from three
punches of 3 mm from 226 Spot Saver Cards (catalog
number GR2261003; PerkinElmer, Waltham, MA) using a
QIAamp DNA Investigator Kit (Qiagen), according to the
manufacturer’s protocol, with 50 mL of distilled water for
the ﬁnal elution step. For evaluation of the stability of the
extract, all of the samples were stored at 4C, except for four
DBSs, which were extracted in duplicate and stored at
20C; the obtained data did not reveal any differences.
Conﬁrmatory Methods
The detection and characterization of all CFTR mutations in
all of the subjects included in this study were also performedjmd.amjpathol.org - The Journal of Molecular Diagnostics
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methods were applied before 188-CF-NGS in validation
steps 1, 2, and 5 and after 188-CF-NGS in validation steps 3
and 4 (Figure 1). We called this group of methods conﬁr-
matory methods. Overall, each mutation that was identiﬁed
by the 188-CF-NGS assay was always detected, in the same
sample, by at least one other conﬁrmatory method. A list of
conﬁrmatory methods and their brief descriptions are re-
ported in the following sections.
Mass Spectrometry Assay
A mass spectrometry assay was conducted using a
Myriapod Cystic Fibrosis Kit SQ080 (Sequenom, San
Diego, CA), which can detect 80 mutations (including eight
deletions) and the Tn tract of CFTR, according to the
manufacturer’s protocol. Brieﬂy, DNA was ampliﬁed by
multiplex PCR using eight different mixes of primers to
obtain fragments corresponding to all of the regions of in-
terest. The PCR products were treated with shrimp alkaline
phosphatase (included in the SQ080 kit) to remove residual
nucleotides. Then, a primer extension reaction (iPlex) with
mass-modiﬁed nucleotides was performed, providing wild-
type and mutant analytes of known mass. After puriﬁca-
tion and chip loading, analysis by the mass spectrometry
platform resolved each analyte by its molecular weight. The
obtained data were analyzed using a MassArray Analyser4
device and iGenetics Myriapod software version 4.0 (Dia-
tech Pharmacogenetics, Jesi, Italy). The mass spectrometry
assay was used for genetic characterization of the 48 DBS
samples before the 188-CF-NGS assay preliminary valida-
tion (ﬁrst validation step, Study Design and Case Series).42
Sanger Sequencing
The regions of interest were ampliﬁed by PCR using
Sensoquest Thermal Cyclers (Biomedizinische Elektronik,
Hamburg, Germany). The PCR products were subse-
quently subjected to automated puriﬁcation with a Biomek
3000 device (Beckman Coulter, Nyon, Switzerland) and
Agentcourt chemistry (Beckman Coulter), followed by
automated cycle sequencing with the Big Dye Terminator
Cycle Sequencing Kit version 1.1 (Life Technologies, New
York, NY).29 Electrophoresis was performed on the ABI
PRISM 3130xl platform (Life Technologies). Data analysis
was performed with Sequencing Analysis software version
5.3.1 (Life Technologies) and then visualized with Seq-
Scape software version 2.1.1 (Life Technologies).43 In
addition to the prior genetic characterization of the 24
genomic samples used for NGS preliminary validation
(second validation step, Study Design and Case Series),
and the prior genetic characterization of a subset of the
case series of 1138 CF patients (ﬁfth validation step, Study
Design and Case Series), Sanger sequencing was also used
as a conﬁrmatory tool for the identiﬁed mutations in the
188-CF-NGS assay (those which were suitable to be
characterized by sequencing) in the third and fourth vali-
dation steps.The Journal of Molecular Diagnostics - jmd.amjpathol.orgCF-OLA Assay
The CF-OLA assay (Abbott, Wiesbaden, Germany) was
used for the prior genetic characterization of a subset of the
case series of 1138 CF patients (ﬁfth validation step, Study
Design and Case Series) according to the manufacturer’s
protocol. Electrophoresis was performed on the ABI PRISM
3130xl platform.
CFTR Core and CFTR Italia Assays
The CFTR Core and CFTR Italia version 2 assays
(Devyser, Hagersten, Sweden) were used for the prior ge-
netic characterization of a subset of the case series of 1138
CF patients (ﬁfth validation step, Study Design and Case
Series). They were also used to conﬁrm and characterize
the macrodeletions found by the 188-CF-NGS assay (those
which were included in these Devyser assays) in the third
and fourth validation steps. They were applied following
the manufacturer’s protocol. Electrophoresis was performed
on the ABI PRISM 3130xl platform.
RDB-Inno LiPA CFTR17þTn Update, CFTR19, CFTR Italian
Regional and CFTR Deletions þ6
RDB-Inno LiPA CFTR17þTn Update, CFTR19, CFTR
Italian Regional and CFTR Deletions þ6 (Fujirebio Europe,
Gent, Belgium) were used for the prior genetic character-
ization of a subset of the case series of 1138 CF patients
(ﬁfth validation step, Study Design and Case Series) ac-
cording to the manufacturer’s protocol.
MLPA
MLPA was performed by using the Salsa MLPA P091-D1
CFTR probe mix and reagent kit according to the manu-
facturer’s protocol (MRC-Holland, Amsterdam, the
Netherlands). Electrophoresis was performed on the ABI
PRISM 3130xl platform. The data analysis was performed
using the Coffalyser.net software version 140721.1958
(MRC-Holland). MLPA was used for the prior macro-
deletion and macroduplication detection in samples from a
subset of the case series of 1138 CF patients (ﬁfth vali-
dation step, Study Design and Case Series). MLPA was
also used to conﬁrm the macrodeletions and macro-
duplications that were identiﬁed by the 188-CF-NGS assay
(in the third and fourth validation steps) and were not
included in the Devyser assays. In these cases, the break-
points were characterized by Sanger sequencing.
NGS
The NGS experiments were performed using the commer-
cial CFTR MASTR Dx version 2 assay (Multiplicom, Niel,
Belgium). This assay enabled the targeted, multiplex PCR
ampliﬁcation of all coding regions, selected intronic regions,
and part of the promoter region of CFTR, in a limited
number of PCR reactions. In the ﬁrst step, all targeted re-
gions were ampliﬁed in two separate multiplex PCR
ampliﬁcation reactions per individual, using a hot-start791
Lucarelli et alDNA polymerase. In the second step, a second round of
PCR, which allowed tagging of the amplicons with molec-
ular identiﬁers and MiSeq adaptors, was performed. The
resulting tagged amplicons were visualized for quality
control through ﬂuorescent labeling and capillary electro-
phoresis on ABI PRISM 3130xl and were then pooled per
individual. Each pooled amplicon library was subsequently
puriﬁed from small residual DNA fragments with AMPure
beads (Beckman Coulter), and the DNA concentration was
determined by the Qubit dsDNA BR Assay Kit (Life
Technologies). Next, puriﬁed and individually tagged
amplicon libraries were pooled in equimolar samples (9
pmol/L each), along with 5% PhiX as a control (Illumina,
San Diego, CA). The resulting amplicon pools were further
processed on a MiSeq System with the 2  250 reagent kit
and the MiSeq Reagent Nano kit version 2 (Illumina) ac-
cording to the manufacturer’s recommendations.
NGS Data Analysis
Data produced by the 188-CF-NGS assay were analyzed
starting from the FastQ ﬁles generated by the MiSeq System
(Illumina) using Data Driven Medicine software version
4.2.5 (Sophia Genetics, Ecublens, Switzerland).
The FastQ ﬁles were automatically uploaded and pro-
cessed using patented advanced algorithms, generating a
report of the entire mutation panel. For each mutation, the
system speciﬁed the legacy name, its status (present/absent),
the reference used for the alignment, the number of reads,
and the chromosome position. When a mutation was pre-
sent, the platform detailed the exon (and codon) or intron
position, Human Genome Variation Society nomenclature at
the DNA level and, when indicated, at the protein level, as
well as the variant frequency percentage to deﬁne zygosity.
Results
Quality Metrics of the Runs
All of the runs yielded a median cluster density of 887 K/mm2
(minimum 577, maximum 1080).
The mean base-call quality in each sequencing cycle was
very high and typically declined slightly toward the end of
the read. The distribution of mean read qualities in each data
set resulted in a peak of approximately 35 to 40. The dis-
tribution of raw read lengths resulted in one or more peaks
at the end of the x-scale. Regarding mapping quality, most
of the mappings were of high quality, with one peak of
approximately 40. If a read could not be aligned over its full
length, some bases were soft-clipped at the borders of the
read. However, a very small number of bases (4.50% on
average) were clipped.
The mean numbers of bases and reads generated in the
runs were 631.41 Mbp and 2,408,900, respectively. A read
was categorized as unmapped (mean, 0.60%) if it did not
align to the genome, as off target (mean, 0.31%) if it was792aligned but not within the targeted amplicons, and as on
target (mean, 99.09%) if it was mapped within the ampli-
con regions. None of the samples in any run had <85% of
reads mapping to the amplicon regions. The mean per-
centage of bases called incorrectly at any one cycle was
1.33% (error rate), whereas the mean percentage of bases
with a quality score of 30 or higher was 95.07%. The
median percentage of single clusters with a clear signal in
the bases sequenced, indicated by passing ﬁlter percentage,
was 95.60%.
An important prerequisite for reliable variant detection
from NGS data was the coverage of targeted regions. The
base coverage was deﬁned as the number of reads covering
a base. The coverage of an amplicon on a targeted region
was deﬁned as its mean base coverage. There was no re-
gion that fell within amplicons with a coverage of <50. In
fact, the mean coverage achieved in the samples subjected
to NGS analysis was 638 reads for each amplicon. In
addition, the minimum/maximum respective values were
147/3303.
CFTR Mutations Detected by the 188-CF-NGS Assay and
Validation
In Supplemental Table S1, the mutations detected by the
188-CF-NGS assay are indicated according to both the old
nomenclature (legacy name) and new nomenclature (Human
Genome Variation Society), whereas in the text they are
indicated according to legacy name only. In Table 1, each
mutation is assigned to the validation step in which it was
ﬁrst identiﬁed, although several mutations were identiﬁed
several times in different validation steps. To date, we have
analyzed 1828 samples and used a case series comprising
1138 CF patients (Materials and Methods) (Figure 1). For
validation steps 1 and 2, 48 DBS and 24 genomic DNA
samples with known mutations, respectively, were analyzed.
For validation steps 3 and 4, 1378 DBSs from neonatal
screening and 378 genomic DNA samples with unknown
mutations, respectively, were analyzed. For validation step
5, samples from a case series of 1138 CF patients with
known CFTR genotype were used. Step 6 was a theoretical
validation of the mutations that were not found in steps 1 to
4 and were not represented in our case series.
In the 48 DBSs (validation step 1) (Table 1), we selected
one small deletion (F508del), one small insertion
(4016insT), four nonsense mutations (G542X, Q552X,
R1162X, and W1282X), six missense mutations (T338I,
D1152H, N1303K, R1066H, R117C, and R117H), and two
splicing mutations (1898þ1G>A and 3849þ10kbC>T). In
this step we validated 14 different mutations.
The analysis of the 24 genomic DNA samples (validation
step 2) (Table 1) identiﬁed the following mutations: four
small deletions (F508del, 1782delA, 4382delA, and 1002-
1110_1113delTAAG), four nonsense mutations (E585X,
G542X, Q552X, and R1162X), eight missense mutations
(D1152H, G1244E, L1077P, L206W, N1303K, R1066H,jmd.amjpathol.org - The Journal of Molecular Diagnostics
An NGS Mutation Panel for Cystic FibrosisR117C, and R347P), and two splicing mutations (1717-
1G>A and 3849þ10kbC>T). In this step, we validated 18
different mutations, 9 of which were in addition to those
from the previous step. In the ﬁrst two steps, we validated a
total of 23 different CFTR mutations.
All of the mutations found by the 188-CF-NGS assay
within the ﬁrst and second validation steps were correctly
identiﬁed with respect to a prior genetic characterization of
the same samples by a conﬁrmatory method (Materials and
Methods).
Among the 1378 samples selected by neonatal screening
with elevated levels of immunoreactive trypsinogen (vali-
dation step 3) (Table 1), we identiﬁed 28 CF neonates (6
homozygotes and 22 compound heterozygotes) and 141
heterozygotes, with a negative sweat test. In 9 CF newborns
(1 homozygote and 8 compound heterozygotes) and in 29
heterozygotes, we were able to identify 16 mutations that
would not have been detected with other methods because
they were not present in the mutation panels that we pre-
viously used for genetic analysis of newborns who were
positive on neonatal screening. An overall number of 49
different mutations were found, 32 of which were additional
to those identiﬁed using the previous two validation steps.
In these three steps, we validated a total of 55 mutations.
Among the 378 genomic DNA samples (validation step 4)
(Table 1), we identiﬁed 93 heterozygotes. Overall, 36
different mutations were found, 15 of which were additional
to those identiﬁed using the previous three validation steps. In
these four steps, we validated a total of 70 CFTR mutations.
In the third and fourth validation steps, all of the muta-
tions found by the 188-CF-NGS assay were conﬁrmed in a
subsequent genetic characterization of the same samples by
a conﬁrmatory method (Materials and Methods).
In samples from the case series of 1138 CF patients (vali-
dation step 5) (Table 1), 84 mutations that were not validated
in the previous four steps were selected, and samples from the
corresponding patients were analyzed by the 188-CF-NGS
assay for validation. In all of the samples analyzed in this step,
all of the mutations found by the 188-CF-NGS assay were
correctly identiﬁed with respect to a prior genetic character-
ization of the same samples by a conﬁrmatory method
(Materials andMethods). In all of the ﬁve validation steps, we
validated a total of 154 different CFTR mutations of the 188
included in the 188-CF-NGS assay.
After the ﬁve validation steps, an overall number of 34
mutations were left with only theoretical validation (vali-
dation step 6) (Table 1).
Finally, the 188-CF-NGS mutation panel consisted of 188
CFTR mutations, 154 of which were experimentally vali-
dated and 34 were theoretically validated.
Macrodeletions, Macroduplications, and Complex
Alleles in the 188-CF-NGS Assay
The 188-CF-NGS assay can detect each macrodeletion and
macroduplication listed in Supplemental Table S1. If theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmacrodeletion or macroduplication breakpoints are not
known, a general Human Genome Variation Society nota-
tion is used. By contrast, whenever a macrodeletion or a
macroduplication with characterized breakpoints exists, the
speciﬁc Human Genome Variation Society name is re-
ported. With this method, it may not be possible to directly
infer the breakpoints of the identiﬁed macrodeletion or
macroduplication. In these cases, further studies are needed
to complete the structural characterization.
Some of the mutations included in the 188-CF-NGS
assay have also been found within complex alleles. A brief
description of these mutations and the corresponding com-
plex alleles, as well as their prevalences in this case series of
CF patients, are reported in Supplemental Table S2.Operative Characteristics of the Assay
All of the 154 experimentally validated mutations, both
those that were already known to be present and those that
were ﬁrst revealed by the 188-CF-NGS assay and then
conﬁrmed by a conﬁrmatory method, were correctly
revealed in every tested sample and replicate. Similarly,
every wild-type sample and replicate was correctly charac-
terized as negative by the 188-CF-NGS assay. Conse-
quently, we can assign a value of 100% to the analytical
sensitivity and analytical speciﬁcity of the 188-CF-NGS
assay. None of the replicated samples showed discrepant
results, allowing an estimation of 100% reproducibility.
The DRs (diagnostic sensitivity) of the 188-CF-NGS
assay were 95.0% in the Lazio case series and 95.6% in the
Lombardia case series (Table 1). As we found no false-
positive results, we also report 100% overall diagnostic
speciﬁcity.
The pipeline was fully automated. From an experimental
point of view, the turnaround time of the platform for the
complete assay in a single NGS analytical run of up to 52
samples simultaneously was 3 working days.Discussion
This study is one of the ﬁrst to apply a customized,
geographically matched panel for CF disease-causing mu-
tations using NGS technology. We validated this NGS-
based assay (which we called the 188-CF-NGS assay),
generating a customized panel of 188 CFTR mutations. This
assay showed DRs of 95.0% and 95.6% in central and
northern Italy, respectively, as deduced from the analysis of
samples from two large-scale case series of Italian patients
with CF. This assay also showed excellent values of all of
the other analytical and diagnostic operative characteristics.
Due to the complex genetics and genotypeephenotype
relationship of CF, an unequivocal mutation search strategy
has not been delineated yet. It has been evidenced that a
unique genetic test suitable for diagnostic and neonatal and
carrier screening programs, as well as for all clinical forms793
Table 1 Characteristics and Frequency of Mutations Included in the 188-CF-NGS Assay
Legacy name Validation step Type of mutation Classiﬁcation in CFTR2
Prevalence CF
(PI þ PS) Lazio
Prevalence CF
(PI þ PS) Lombardia
n Frequency n Frequency
CFTR-dup 1e3 5 Duplication ND 0 0.000 1 0.001
M1V 5 Missense CF-causing 1 0.001 3 0.002
CFTRdele1 5 Deletion CF-causing 0 0.000 1 0.001
P5L 3 Missense ND 2 0.002 1 0.001
L15P 5 Missense ND 0 0.000 1 0.001
175insT 4 Insertion ND 0 0.000 0 0.000
186-13C>G 6 Splicing ND 0 0.000 0 0.000
CFTRdele2,3 5 Deletion CF-causing 3 0.003 3 0.002
CFTRdele2ins182 6 Deletion/Insertion ND 0 0.000 0 0.000
CFTRdele2 5 Deletion CF-causing 3 0.003 6 0.005
Q39X 6 Nonsense CF-causing 0 0.000 0 0.000
296þ2T>G 5 Splicing ND 1 0.001 1 0.001
E60X 6 Nonsense CF-causing 0 0.000 0 0.000
L61P 6 Missense ND 0 0.000 0 0.000
R75X 5 Nonsense CF-causing 0 0.000 1 0.001
G85E 3 Missense CF-causing 34 0.035 13 0.010
394delTT 5 Deletion CF-causing 0 0.000 1 0.001
406-1G>C 5 Splicing ND 0 0.000 1 0.001
CFTRdele4 3 Deletion ND 0 0.000 1 0.001
CFTRdele4-10 5 Deletion ND 0 0.000 1 0.001
E92K 6 Missense CF-causing 0 0.000 0 0.000
K95E 5 Missense ND 0 0.000 1 0.001
457TAT>G 5 Deletion/Insertion CF-causing 0 0.000 2 0.002
D110H 5 Missense CF-causing 5 0.005 0 0.000
D110E 6 Missense ND 0 0.000 0 0.000
R117C 1 Missense CF-causing 3 0.003 5 0.004
R117H 1 Missense Varying 0 0.000 3 0.002
R117L 5 Missense ND 6 0.006 0 0.000
G126D 3 Missense ND 1 0.001 0 0.000
541delC 5 Deletion CF-causing 0 0.000 3 0.002
541del4 6 Deletion ND 0 0.000 0 0.000
546insCTA 5 Insertion ND 0 0.000 1 0.001
H139R 5 Missense ND 4 0.004 0 0.000
H147P 4 Missense ND 0 0.000 0 0.000
574delA 3 Deletion CF-causing 3 0.003 0 0.000
621þ1G>T 5 Splicing CF-causing 8 0.008 1 0.001
663insT 5 Insertion ND 0 0.000 1 0.001
G178R 5 Missense CF-causing 3 0.003 3 0.002
E193K 3 Missense ND 0 0.000 0 0.000
711þ1G>T 5 Splicing CF-causing 5 0.005 3 0.002
711þ3A>G 4 Splicing CF-causing 1 0.001 5 0.004
711þ5G>A 5 Splicing CF-causing 0 0.000 7 0.005
H199R 5 Missense ND 1 0.001 0 0.000
P205S 6 Missense CF-causing 0 0.000 0 0.000
L206W 2 Missense CF-causing 0 0.000 3 0.002
G213E 5 Missense ND 0 0.000 3 0.002
Q220X 5 Nonsense CF-causing 1 0.001 0 0.000
852del22bp 3 Deletion CF-causing 1 0.001 6 0.005
875þ1G>A 6 Splicing ND 0 0.000 0 0.000
C276X 5 Nonsense CF-causing 2 0.002 0 0.000
991del5 5 Nonsense CF-causing 1 0.001 0 0.000
1002-1110_1113delTAAG 2 Deletion ND 0 0.000 3 0.002
1002-1111A>C 4 Splicing ND 0 0.000 0 0.000
A309D 5 Missense ND 0 0.000 1 0.001
1078delT 5 Deletion CF-causing 0 0.000 1 0.001
(table continues)
Lucarelli et al
794 jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 (continued )
Legacy name Validation step Type of mutation Classiﬁcation in CFTR2
Prevalence CF
(PI þ PS) Lazio
Prevalence CF
(PI þ PS) Lombardia
n Frequency n Frequency
R334W 3 Missense CF-causing 8 0.008 8 0.006
R334L 5 Missense ND 5 0.005 0 0.000
T338I 1 Missense CF-causing 5 0.005 7 0.005
R347H 5 Missense CF-causing 3 0.003 2 0.002
R347P 2 Missense CF-causing 7 0.007 7 0.005
R352W 3 Missense ND 0 0.000 0 0.000
R352Q 3 Missense CF-causing 0 0.000 14 0.011
Q353X 6 Nonsense ND 0 0.000 0 0.000
1248þ1G>A 5 Splicing CF-causing 0 0.000 2 0.002
1249-1G>A 5 Splicing CF-causing 0 0.000 1 0.001
1259InsA 3 Insertion CF-causing 1 0.001 1 0.001
1497delGG 6 Deletion CF-causing 0 0.000 0 0.000
V456A 6 Missense ND 0 0.000 0 0.000
G463D 4 Missense ND 0 0.000 0 0.000
K464N 5 Missense ND 0 0.000 2 0.002
S466X(TAA) 3 Nonsense CF-causing 0 0.000 0 0.000
S466X(TGA) 5 Nonsense CF-causing 3 0.003 0 0.000
1565delCA 6 Deletion ND 0 0.000 0 0.000
Q493X 6 Nonsense ND 0 0.000 0 0.000
E504X 5 Nonsense ND 0 0.000 1 0.001
[delta]I507 5 Deletion CF-causing 0 0.000 1 0.001
[delta]F508 1 Deletion CF-causing 440 0.447 608 0.471
1677delTA 3 Deletion CF-causing 0 0.000 3 0.002
Q525X 6 Nonsense CF-causing 0 0.000 0 0.000
1706del17 6 Deletion ND 0 0.000 0 0.000
CFTRdele11 4 Deletion CF-causing 0 0.000 0 0.000
1716þ18672A>G 5 Splicing ND 0 0.000 4 0.003
1717-8G>A 5 Splicing CF-causing 2 0.002 1 0.001
1717-1G>A 2 Splicing CF-causing 15 0.015 41 0.032
G542X 1 Nonsense CF-causing 43 0.044 64 0.050
S549R(A>C) 5 Missense CF-causing 12 0.012 0 0.000
S549N 5 Missense CF-causing 2 0.002 1 0.001
S549R(T>G) 4 Missense CF-causing 7 0.007 0 0.000
1782delA 2 Deletion CF-causing 0 0.000 4 0.003
1784delG 5 Deletion ND 0 0.000 1 0.001
G551D 5 Missense CF-causing 1 0.001 0 0.000
Q552X 1 Nonsense CF-causing 1 0.001 1 0.001
R553X 5 Nonsense CF-causing 13 0.013 12 0.009
V562I 3 Missense ND 0 0.000 1 0.001
Y563X 5 Nonsense ND 0 0.000 2 0.002
L571S 5 Missense ND 1 0.001 1 0.001
1845delAG/1846delGA 5 Deletion ND 0 0.000 1 0.001
D579G 3 Missense Varying 1 0.001 5 0.004
1874insT 6 Insertion ND 0 0.000 0 0.000
E585X 2 Nonsense CF-causing 3 0.003 11 0.009
S589I 4 Missense ND 0 0.000 0 0.000
1898þ1G>A 1 Splicing CF-causing 0 0.000 5 0.004
1898þ3A>G 6 Splicing CF-causing 0 0.000 0 0.000
1898þ5G>T 5 Splicing ND 0 0.000 1 0.001
S589R 4 Missense ND 0 0.000 0 0.000
K598X 5 Nonsense ND 0 0.000 1 0.001
1949del84 4 Deletion ND 0 0.000 0 0.000
H609R 5 Missense ND 0 0.000 2 0.002
A613T 5 Missense ND 1 0.001 1 0.001
D614G 4 Missense Varying 6 0.006 0 0.000
(table continues)
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Table 1 (continued )
Legacy name Validation step Type of mutation Classiﬁcation in CFTR2
Prevalence CF
(PI þ PS) Lazio
Prevalence CF
(PI þ PS) Lombardia
n Frequency n Frequency
H620P 5 Missense ND 0 0.000 1 0.001
2118del4 3 Deletion CF-causing 0 0.000 1 0.001
2143delT 5 Deletion CF-causing 1 0.001 0 0.000
G673X 6 Nonsense CF-causing 0 0.000 0 0.000
2183AA>G 3 Deletion/Insertion CF-causing 12 0.012 20 0.015
2184delA 6 Deletion CF-causing 0 0.000 0 0.000
2184insA 5 Insertion CF-causing 6 0.006 2 0.002
2185insC 6 Insertion CF-causing 0 0.000 0 0.000
R709X 5 Nonsense CF-causing 3 0.003 0 0.000
Q720X 5 Nonsense ND 0 0.000 1 0.001
2307insA 6 Insertion CF-causing 0 0.000 0 0.000
L732X 5 Nonsense CF-causing 2 0.002 1 0.001
R764X 5 Nonsense CF-causing 1 0.001 0 0.000
R785X 3 Nonsense CF-causing 0 0.000 1 0.001
2585delT 6 Deletion CF-causing 0 0.000 0 0.000
E822X 4 Nonsense CF-causing 0 0.000 0 0.000
E831X 5 Nonsense CF-causing 1 0.001 2 0.002
Y849X 5 Nonsense CF-causing 1 0.001 0 0.000
R851X 5 Nonsense CF-causing 0 0.000 1 0.001
2711delT 5 Deletion CF-causing 0 0.000 1 0.001
CFTRdele14b-17b 5 Deletion CF-causing 1 0.001 5 0.004
W882X 5 Nonsense ND 0 0.000 1 0.001
2789þ5G>A 3 Splicing CF-causing 40 0.041 39 0.030
2790-2A>G 5 Splicing ND 1 0.001 0 0.000
2811G>T 6 Splicing ND 0 0.000 0 0.000
S912X 3 Nonsense CF-causing 1 0.001 0 0.000
2909delT 6 Deletion ND 0 0.000 0 0.000
S945L 5 Missense CF-causing 2 0.002 1 0.001
G970R 6 Missense CF-causing 0 0.000 0 0.000
CFTRdele17a-18 3 Deletion CF-causing 4 0.004 2 0.002
3121-2A>T 6 Splicing CF-causing 0 0.000 0 0.000
3121-1G>A 6 Splicing CF-causing 0 0.000 0 0.000
3132delTG 6 Deletion CF-causing 0 0.000 0 0.000
A1006E 5 Missense ND 0 0.000 1 0.001
[V562I;A1006E] 5 Complex Allele ND 9 0.009 1 0.001
Q1012X 4 Nonsense ND 0 0.000 0 0.000
3199del6 6 Deletion ND 0 0.000 0 0.000
Y1032C 3 Missense ND 0 0.000 0 0.000
CFTRdele17b 5 Deletion ND 0 0.000 1 0.001
3272-26A>G 3 Splicing CF-causing 1 0.001 2 0.002
H1054D 5 Missense CF-causing 0 0.000 1 0.001
L1065P 5 Missense CF-causing 6 0.006 0 0.000
R1066C 3 Missense CF-causing 5 0.005 9 0.007
R1066H 1 Missense CF-causing 1 0.001 23 0.018
F1074L 3 Missense Varying 0 0.000 1 0.001
L1077P 2 Missense CF-causing 12 0.012 15 0.012
M1101K 5 Missense CF-causing 0 0.000 2 0.002
E1104X 3 Nonsense CF-causing 0 0.000 1 0.001
W1145X 5 Nonsense ND 0 0.000 1 0.001
D1152H 1 Missense Varying 7 0.007 23 0.018
R1158X 3 Nonsense CF-causing 0 0.000 10 0.008
[R334W;R1158X] 3 Complex Allele ND 0 0.000 0 0.000
R1162X 1 Nonsense CF-causing 3 0.003 4 0.003
3659delC 4 Deletion CF-causing 0 0.000 2 0.002
S1206X 5 Nonsense ND 1 0.001 1 0.001
(table continues)
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Table 1 (continued )
Legacy name Validation step Type of mutation Classiﬁcation in CFTR2
Prevalence CF
(PI þ PS) Lazio
Prevalence CF
(PI þ PS) Lombardia
n Frequency n Frequency
M1210K 5 Missense ND 0 0.000 2 0.002
I1234V 5 Missense CF-causing 3 0.003 0 0.000
3849þ10kbC>T 1 Splicing CF-causing 9 0.009 21 0.016
G1244E 2 Missense CF-causing 4 0.004 8 0.006
3876delA 6 Deletion CF-causing 0 0.000 0 0.000
3878delG 5 Deletion CF-causing 0 0.000 1 0.001
S1251N 5 Missense CF-causing 0 0.000 1 0.001
3905insT 3 Insertion CF-causing 0 0.000 0 0.000
D1270N 3 Missense Varying 1 0.001 0 0.000
W1282X 1 Nonsense CF-causing 47 0.048 19 0.015
Q1291R 3 Missense ND 3 0.003 0 0.000
CFTRdele21 5 Deletion ND 0 0.000 1 0.001
4015delA 5 Deletion CF-causing 0 0.000 3 0.002
4016insT 1 Insertion CF-causing 1 0.001 15 0.012
4040delA 5 Deletion CF-causing 2 0.002 0 0.000
N1303K 1 Missense CF-causing 61 0.062 64 0.050
Q1313X 6 Nonsense CF-causing 0 0.000 0 0.000
CFTRdele22-24 5 Deletion/Insertion CF-causing 7 0.007 3 0.002
CFTRdele22-23 4 Deletion CF-causing 1 0.001 4 0.003
G1349D 3 Missense CF-causing 2 0.002 1 0.001
4209TGTT>AA 6 Deletion/Insertion CF-causing 0 0.000 0 0.000
H1375P 5 Missense ND 3 0.003 2 0.002
4382delA 2 Deletion CF-causing 0 0.000 6 0.005
S1455X 3 Nonsense ND 1 0.001 1 0.001
E1473X 5 Nonsense ND 0 0.000 2 0.002
Detected alleles 935 1235
Unknown alleles 49 57
Overall alleles 984 1292
Detection rate 0.950 (95.0%) 0.956 (95.6%)
The mutations are listed only in old nomenclature (legacy name; refer to Supplemental Table S1 for Human Genome Variation Society nomenclature). The
Validation step column refers to the following validation procedures (Materials and Methods): 1 Z validated in the ﬁrst step by the selected 48 dried blood
spots (DBSs); 2Z validated in the second step by the selected 24 genomic DNA; 3Z validated in the third step by the subsequent 1378 DBSs; 4Z validated
in the fourth step by the subsequent 378 genomic DNA; 5Z validated in the ﬁfth step by the 1138 cystic ﬁbrosis (CF) patient case series; 6Z validated only
at theoretic level. The type of mutations and the functional classiﬁcation according to CFTR2 database is reported. The prevalence of each mutation in both the
Lazio and Lombardia case series is reported as number (n) and frequency of alleles; the corresponding DRs are also shown.
CF-causing, mutation that causes classic form of CF; ND, mutation not reported in the CFTR2 database; PI, pancreatic insufﬁciency; PS, pancreatic sufﬁ-
ciency; Varying, mutation with variable clinical effect.
An NGS Mutation Panel for Cystic Fibrosisof CF, does not exist.17 A multistep genetic approach is
usually applied for diagnostic purposes.5,17 The ﬁrst step is
to search for a panel of frequent CFTR mutations. The DRs
of CF mutation panels are different in diverse populations33
and depend on the clinical form.17 Consequently, this step
leaves a variable proportion of alleles with no mutation
detected. To characterize these unknown alleles, a second
step of sequencing (usually sequencing of all of the exons,
adjacent intronic zones, and proximal 50-ﬂanking region of
CFTR) is applied. Sequencing of CFTR, when applied for
diagnostic purposes based on either classic Sanger
sequencing or NGS, is reported to detect approximately
97% of disease-causing mutations, at least in CF.5,17,44 In
CFTRerelated disorders and congenital bilateral absence of
vas deferens, even sequencing may have a low DR.5,17,44
Those mutations possibly not recognized, for exampleThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmacrodeletions and macroduplications, are usually investi-
gated in a third step of mutation search to reveal CNVs. It is
expected that this step will add up to 2% to the DR.
Although a sequencing protocol, possibly followed by a
CNV search, may be suitable for diagnostic purposes, it
does not appear to be recommendable for carrier or neonatal
screening. This is especially true if a powerful approach,
such as NGS, is used.45 The DR of an extended mutation
panel by NGS, including frequent and characterized CNVs,
usually is sufﬁciently high for carrier and neonatal screening
purposes. On the other hand, sequencing (and in some cases
also CNV analysis) may identify not only disease-causing
mutations possibly undetected by commonly used panels,
but also novel or rare CFTR variants the clinical signiﬁcance
of which has not been assessed, or variants associated with a
broad phenotypic spectrum. In addition, novel CNVs797
Lucarelli et alusually need further structural characterization. When
mutation-identiﬁcation assays, such as sequencing, are used,
novel variants are identiﬁed in an estimated w1 in 500
samples that are tested for carrier status.46 In addition, to
limit costs and time, even for diagnostic purposes in CF, it
may be suitable to start the mutation search with a mutation
panel. For these reasons, protocols based on mutation panels
still have a role in mutational searches performed for both
CF diagnostics and screening purposes, even in the NGS
era.
The DR reached by our 188-CF-NGS assay is among the
highest achieved by a genetic test for CF based on a mutation
panel (level I assay) in a population with high genetic het-
erogeneity of CFTR. For example, the Food and Drug
Administrationeapproved MiSeqDX Cystic Fibrosis 139-
variant assay (Illumina), an NGS mutation panel that was
not speciﬁcally optimized for central or northern Italy, shows
DRs considerably lower than that of our assay in both regions
of Italy (central, 86.8%; northern, 86.9%), as deduced from
the analysis of data from our case series. This result high-
lights that, despite the power of extended mutation panels
based on NGS technology, customization is still required to
achieve maximal DRs in speciﬁc geographic areas and,
conceivably, in ethnicities and clinical forms. Moreover,
there may be geographic areas with even higher genetic
heterogeneity than that of Italy where a similarly high DR
may not be reached, even with a widely targeted NGS mu-
tation panel. Although the deﬁnition of a mutation search as a
ﬁrst-level test is irrespective of the number of mutations
included in the panel, it is evident that NGS greatly enhances
this approach by using wider mutation panels. Owing to this
enhancement, the gap between the DRs shown by the same
mutation panel in different geographic areas, ethnicities, and
CF clinical forms will decrease. However, due to rare and
often individual mutations17 and high geographic heteroge-
neity, the use of only one large mutation panel that is suitable
for all purposes remains unlikely.
A common problem of mutation panels is that of com-
plex alleles, which contain more than one mutation in cis.
It is becoming clear that complex alleles occur more
frequently than is usually recognized. We chose to include
at least one mutation of the most frequent complex alleles
in the 188-CF-NGS assay and to supply a list of mutations
that would have been searched for in cases in which a
potentially associated mutation was found. It is obvious that
the complete panel of mutations within complex alleles can
be easily added to the Data Driven Medicine platform
(Sophia Genetics). Presently, the Data Driven Medicine
platform lets users unmask the analysis of the (TG)mTn
variant tract when one of the following mutations is
detected: R117C, R117H, K464N, V562I, A1006E, or
2184insA (Supplemental Table S2).
The validation of the 188-CF-NGS assay on DBSs
showed excellent operative characteristics that are fully
comparable to those of genomic DNA samples. This result
makes the assay also suitable for the genetic step of neonatal798screening programs, such as the immunoreactive trypsin-
ogen/DNA/immunoreactive trypsinogen protocol.47,48
Another characteristic that makes the 188-CF-NGS assay
attractive is the possibility that when nomutations or only one
mutation is identiﬁed in individuals potentially affected by
CF, a different proﬁling analysis can be applied with the Data
DrivenMedicine platform, unmasking the complete sequence
of CFTR. Furthermore, the CFTR sequence acquired by this
NGS approach can reveal CNVs by analyzing the number of
reads, including the identiﬁcation of CFTR macrodeletions
and macroduplications. The possibility of applying all three
steps of the mutation search (also combining the second and
third steps) according to the requirements of the applied
protocol and by only switching software settings represent
considerable enhancements with respect to previous multi-
step approaches. Improved CFTR genotyping is expected
from the 188-CF-NGS assay due to the speediness,
simplicity, and high-throughput nature of the assay, as well as
its predictable, enhanced identiﬁcation of complex alleles.
As NGS methods are still in the experimental phase,
conﬁrmation by an independent method seems to be appro-
priate. Depending on the type of mutation evidenced, an
appropriate conﬁrmatory method (Materials and Methods)
was applied. There was perfect concordance between the data
obtained with the 188-CF-NGS assay and the conﬁrmatory
methods. Although it may still be untimely to abandon the
conﬁrmatory procedure, these results further highlight the
reliability of NGS-based approaches as stand-alone methods.
A turnaround time of 3 working days for up to 52 samples
seems suitable for overcoming the wait-time issues related
to the collection of an appropriate number of samples. From
a data analysis point of view, the type of analysis can be
selected according to clinical indications. The algorithm of
the Data Driven Medicine platform was speciﬁcally adapted
to our needs to accurately perform DNA sequence assembly,
alignment to the reference genome, variant calling, and
variant annotation in a short time for level I analysis (panel),
and one can easily proceed, if indicated, to analysis levels II
(sequence) and III (macrodeletions/macroduplications).
Also, the (TG)mTn tracts can be easily analyzed if needed.
In conclusion, the 188-CF-NGS assay is a robust method
that is easy to handle and that allows the detection of
approximately 95% of the mutations in the Italian popula-
tion, thus achieving a marked increase in DR compared with
those of other NGS-based mutation panel methods. This
result highlights the concept that despite the high number of
CFTR mutations that can be searched by NGS methods, the
customization of mutation panels for a geographic area and,
conceivably, for ethnicities and clinical forms, is still
advisable. The availability of an extended mutation panel
with a high DR is useful for limiting the use of sequencing
and for avoiding the detection of DNA variants with unclear
functional meaning. It enhances the ability to obtain an
early, complete deﬁnition of mutated genotypes in CF pa-
tients, providing a meaningful genotypic-oriented view of
CFTR genetics.5 Our assay is well suited for CF diagnosticjmd.amjpathol.org - The Journal of Molecular Diagnostics
An NGS Mutation Panel for Cystic Fibrosispurposes, neonatal screening, and carrier screening, and has
also been ﬁnalized for assisted reproductive technology. It
might also show good performance for CFTR-related dis-
orders and congenital bilateral absence of vas deferens;
however, experimental veriﬁcation seems appropriate.
Experimental approaches based on extended panels of mu-
tations for NGS, such as the one described here, greatly
facilitate the task of ﬁnding mutations, providing a better
deﬁnition of the genotypeephenotype relationship. Overall,
these ﬁndings clearly have positive implications for the
genetic counseling of CF. Finally, the synergy between
NGS approaches and the actual possibility of personalized
CF therapy is anticipated to produce unparalleled advan-
tages for CF patients. NGS approaches help to reduce
possibly incomplete genotyping, which may hamper the
therapeutic response to a mutation-speciﬁc therapy. This
enhanced knowledge of CFTR genetics may ﬁnally allow
the physician to apply both predictive and preventive
medicine in CF.49
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